Literature DB >> 31111572

Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study.

Jeong Hoon Lee1, Ji Yong Ahn1, Kee Don Choi1, Hwoon-Yong Jung1, Jung Mogg Kim2, Gwang Ho Baik3, Byung-Wook Kim4, Jun Chul Park5, Hye-Kyung Jung6, Soo Jeong Cho7, Cheol Min Shin8, Yoon Jin Choi8, Si Hyung Lee9, Ji Hyun Kim10, Wan Sik Lee11, Jae Kyu Sung12, Jun-Won Chung13, Dae Young Cheung14, Hyuk Lee15, Yang Won Min15, Jae J Kim15, Seung Young Kim16.   

Abstract

INTRODUCTION: The eradication rates for Helicobacter pylori have decreased in Korea although the prevalence of this bacterium has also decreased. Antibiotic resistance is likely to be a crucial factor in H. pylori eradication success, and we therefore mapped these resistance patterns nationwide in Korea.
MATERIALS AND METHODS: Five hundred and ninety adult subjects were prospectively enrolled from 2017 to 2018 from 15 centers across six geographic areas of Korea. A total of 580 biopsy tissues had been sampled from these patients during an upper endoscopy and were frozen at -80°C and delivered to a central laboratory. The agar dilution method was used to determine the minimum inhibitory concentration of amoxicillin, clarithromycin, metronidazole, tetracycline, ciprofloxacin, and levofloxacin for each H. pylori isolate.
RESULTS: The culture success rate was 60.2% (349/580). Resistance rates against clarithromycin, metronidazole, amoxicillin, tetracycline, levofloxacin, and ciprofloxacin were 17.8%, 29.5%, 9.5%, 0%, 37.0%, and 37.0%, respectively. The geographic distribution of metronidazole and quinolone resistance was highly variable. Some subjects had multiple H. pylori strains in the antrum and body of the stomach and showed a heterogeneous resistance profile between these anatomic areas. The H. pylori multidrug resistance (MDR) rate was 25.2% (88/349) among amoxicillin, clarithromycin, metronidazole, tetracycline, and quinolone and 11.2% (39/349) among four of these major antibiotics except for quinolone. The Seoul and Chungcheong areas showed a relatively lower MDR rate.
CONCLUSION: The antibiotic resistance of H. pylori differs by drug and geographic area in Korea. Detailed nationwide antibiotic resistance mapping is needed to develop an effective H. pylori eradication strategy.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; Korea; antibiotics; resistance

Mesh:

Substances:

Year:  2019        PMID: 31111572     DOI: 10.1111/hel.12592

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  19 in total

1.  Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.

Authors:  Chang Seok Bang; Hyun Lim; Hae Min Jeong; Woon Geon Shin; Jae Ho Choi; Jae Seung Soh; Ho Suk Kang; Young Joo Yang; Ji Taek Hong; Suk Pyo Shin; Ki Tae Suk; Jae Jun Lee; Gwang Ho Baik; Dong Joon Kim
Journal:  Gut Microbes       Date:  2020-05-02

Review 2.  Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea.

Authors:  Jun-Hyung Cho; So-Young Jin
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

Review 3.  Management of Helicobacter pylori Infection: A Comparison between Korea and the United States.

Authors:  Sung Eun Kim; Joo Ha Hwang
Journal:  Gut Liver       Date:  2021-10-25       Impact factor: 4.321

Review 4.  Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Clin Microbiol Rev       Date:  2022-04-11       Impact factor: 50.129

5.  Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.

Authors:  Young-Il Kim; Jong Yeul Lee; Chan Gyoo Kim; Boram Park; Jin Young Park; Il Ju Choi
Journal:  BMC Gastroenterol       Date:  2021-03-02       Impact factor: 3.067

6.  Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia-findings from a molecular based study.

Authors:  Suat Moi Puah; Khean Lee Goh; Heng Kang Ng; Kek Heng Chua
Journal:  PeerJ       Date:  2021-06-09       Impact factor: 2.984

7.  Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.

Authors:  Hye-Kyung Jung; Seung Joo Kang; Yong Chan Lee; Hyo-Joon Yang; Seon-Young Park; Cheol Min Shin; Sung Eun Kim; Hyun Chul Lim; Jie-Hyun Kim; Su Youn Nam; Woon Geon Shin; Jae Myung Park; Il Ju Choi; Jae Gyu Kim; Miyoung Choi
Journal:  Korean J Intern Med       Date:  2021-06-08       Impact factor: 2.884

8.  Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea.

Authors:  Beom Jin Kim; Hyuk Lee; Yong Chan Lee; Seong Woo Jeon; Gwang Ha Kim; Hyun-Soo Kim; Jae Kyu Sung; Dong Ho Lee; Heung Up Kim; Moo In Park; Il Ju Choi; Soon Man Yoon; Sang Wook Kim; Gwang Ho Baik; Ju Yup Lee; Jin Il Kim; Sang Gyun Kim; Jayoun Kim; Joongyup Lee; Jae Gyu Kim; Jae J Kim
Journal:  Gut Liver       Date:  2019-09-15       Impact factor: 4.519

9.  Helicobacter pylori Eradication According to Sequencing-Based 23S Ribosomal RNA Point Mutation Associated with Clarithromycin Resistance.

Authors:  Seung In Seo; Byoung Joo Do; Jin Gu Kang; Hyoung Su Kim; Myoung Kuk Jang; Hak Yang Kim; Woon Geon Shin
Journal:  J Clin Med       Date:  2019-12-25       Impact factor: 4.241

10.  Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.

Authors:  Jue Lie Kim; Soo-Jeong Cho; Su Jin Chung; Ayoung Lee; Jinju Choi; Hyunsoo Chung; Sang Gyun Kim
Journal:  Clin Transl Gastroenterol       Date:  2020-09       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.